SeQure DX Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7M

SeQure DX General Information

Description

Developer of genomics diagnostic technologies designed for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. The company's core technologies enable the identification of all potential off-target sites before initiating therapy, to allow comprehensive confirmation of actual edits, enabling gene editing therapeutics developers, physicians and patients with the confidence needed to ensure safe and effective gene editing therapies.

Contact Information

Website
www.sequre-dx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1440 Main Street
  • Suite 320
  • Waltham, MA 02451
  • United States
Primary Industry
Other Devices and Supplies
Other Industries
Drug Discovery
Biotechnology
Acquirer
MaxCyte
Vertical(s)
Life Sciences
Corporate Office
  • 1440 Main Street
  • Suite 320
  • Waltham, MA 02451
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SeQure DX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 29-Jan-2025 $7M Completed Generating Revenue
3. Early Stage VC 22-Dec-2023 Completed Generating Revenue
2. Early Stage VC Cancelled Generating Revenue
1. Early Stage VC (Series A) 02-Apr-2021 $17.5M $17.5M Completed Generating Revenue
To view SeQure DX’s complete valuation and funding history, request access »

SeQure DX Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view SeQure DX’s complete cap table history, request access »

SeQure DX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of genomics diagnostic technologies designed for gene editor target profiling to advance discovery, clinical d
Other Devices and Supplies
Waltham, MA
20 As of 2025

Cambridge, MA
 

Leiden, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SeQure DX Competitors (26)

One of SeQure DX’s 26 competitors is Arbor Biotechnologies, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arbor Biotechnologies Venture Capital-Backed Cambridge, MA
Ncardia Venture Capital-Backed Leiden, Netherlands
Illumina Formerly VC-backed San Diego, CA
Emulate Venture Capital-Backed Boston, MA
Mammoth Biosciences Venture Capital-Backed Brisbane, CA
You’re viewing 5 of 26 competitors. Get the full list »

SeQure DX Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

SeQure DX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025151661-A1 Methods for single-ended oligonucleotide enrichment and sequencing Inactive 10-Jan-2024
US-20260185152-A1 Methods for selective amplification for efficient rearrangement detection Pending 18-Nov-2022
WO-2024108145-A2 Methods for selective amplification for efficient rearrangement detection Inactive 18-Nov-2022
WO-2024108145-A3 Methods for selective amplification for efficient rearrangement detection Inactive 18-Nov-2022 C12Q1/6869

SeQure DX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SeQure DX Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
BOLD Capital Partners Venture Capital Minority
Casdin Capital Venture Capital Minority
Digitalis Ventures Venture Capital Minority
KdT Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

SeQure DX FAQs

  • When was SeQure DX founded?

    SeQure DX was founded in 2020.

  • Where is SeQure DX headquartered?

    SeQure DX is headquartered in Waltham, MA.

  • What is the size of SeQure DX?

    SeQure DX has 20 total employees.

  • What industry is SeQure DX in?

    SeQure DX’s primary industry is Other Devices and Supplies.

  • Is SeQure DX a private or public company?

    SeQure DX is a Private company.

  • What is the current valuation of SeQure DX?

    The current valuation of SeQure DX is .

  • What is SeQure DX’s current revenue?

    The current revenue for SeQure DX is .

  • How much funding has SeQure DX raised over time?

    SeQure DX has raised $22.3M.

  • Who are SeQure DX’s investors?

    Alexandria Venture Investments, BOLD Capital Partners, Casdin Capital, Digitalis Ventures, and KdT Ventures are 5 of 7 investors who have invested in SeQure DX.

  • Who are SeQure DX’s competitors?

    Arbor Biotechnologies, Ncardia, Illumina, Emulate, and Mammoth Biosciences are some of the 26 competitors of SeQure DX.

  • When was SeQure DX acquired?

    SeQure DX was acquired on 29-Jan-2025.

  • Who acquired SeQure DX?

    SeQure DX was acquired by MaxCyte.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process